Disease‐burden‐adapted immunotherapy protocol for primary refractory or high‐risk relapsed pediatric acute lymphoblastic leukemia

Antzeko izenburuak

• Pre-transplant host status determines the outcomes in non-malignant disorders
  nork: Darshan Kataria, et al.
  Argitaratua: (2024-01-01)
• Risk factors, complement blockade and timely ileostomy for intestinal transplant-associated thrombotic microangiopathy: Lessons learned from a tertiary pediatric hospital
  nork: Sanaa Khan, et al.
  Argitaratua: (2024-01-01)
• The role of graft T-cell size in patients receiving alemtuzumab serotherapy for non-malignant disorders: results of an institutional protocol
  nork: Ambreen Pandrowala, et al.
  Argitaratua: (2024-01-01)
• HLA-mismatched (9 by 10 match) donor HSCT as a feasible alternative for pediatric patients lacking a fully matched donor
  nork: Mahafrin Goiporia, et al.
  Argitaratua: (2025-01-01)
• Narsoplimab for severe transplant-associated thrombotic microangiopathy
  nork: Ambreen Pandrowala, et al.
  Argitaratua: (2023-03-01)